Abilify Risks

Abilify Risks

Abilify, known generically as aripiprazole, was approved by the U.S. Food and Drug Administration (FDA) in 2002 for the treatment of schizophrenia. In 2004 the medication was cleared for the treatment of bipolar disorder. Then in 2007, the FDA approved Abilify as a treatment for major depressive disorder. While this medication  was intended to help people suffering from mental disorders, it has been linked to increased compulsive behavior in patients. As of July 2013, there have been at least eight reported cases of compulsive gambling in patients taking Abilify. In all cases, the urge to gamble also stopped when patients stopped taking Abilify.

Other compulsive behaviors reported by patients after beginning or increasing their dose of Abilify include over- eating, over- shopping, and hypersexuality.

Researchers believe these behaviors are due to the fact that Abilify affects a dopamine receptor in the brain that controls emotions and gives people a sense of pleasure – the D3 receptor, causing compulsive gambling, eating and other out of control behaviors.

This is not the first serious side effect that can be attributed to Abilify. In fact, since it first came on the market, the FDA has issued several warnings concerning Abilify and its side effects. These warnings include:

·       Diabetes and Hyperglycemia: In 2004, the FDA required the manufacturers of atypical antipsychotics, like Abilify, to add warnings about an increased risk of diabetes and hyperglycemia to their labels. These types of drugs can lead to insulin resistance, as they cause the body to metabolize fat instead of carbohydrates. This class of drugs is also known to promote fat accumulation.

·       Death in the Elderly: In 2008, the FDA requested that antipsychotic drugs, including Abilify, update their labels to include a Black Box Warning regarding an increased risk of death when Abilify is used to treat dementia in older patients. Notably The FDA has not approved Abilify for the treatment of dementia in the elderly.

·       Suicide: In 2007, the FDA ordered that the label for drugs like Abilify be updated to include a Black Box Warning regarding an increased risk of suicide in patients under the age of 24.

·       Problems in Newborns: In 2011, the FDA warned that women who were pregnant or planning to become pregnant should be aware that Abilify may cause abnormal muscle movements known as EPS and withdrawal symptoms in infants who were exposed to the medication during the third trimester.

Contact an Abilify Compulsive Behavior Attorney Today.

If you or a loved one has experienced any of the above compulsive behaviors or other signs or symptoms after using Abilify, contact an experienced attorney at Kelley, Bernheim & Dolinsky, LLC today. We will work tirelessly to ensure you receive the compensation you are entitled to.